Upadacitinib for Refractory Alopecia Areata Unresponsive to Prior Systemic Therapies: A Retrospective Study

Published: 5 February 2025| Version 1 | DOI: 10.17632/cyygxjztsb.1
Contributor:
Wang Qin

Description

Supplemental figure I showing the efficacy of Upadacitinib; Supplemental table Idetailing baseline SALT scores, changes in SALT scores, and serum IgE levels for each patient with refractory alopecia areata following treatment with Upadacitinib; Supplementary Table II. Correlation between characteristics of alopecia areata patients treated with upadacitinib and percentage of hair regrowth at week 24w.

Files

Institutions

Huashan Hospital Fudan University

Categories

Hair Disorder

Licence